SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Cathcart who wrote (1066)7/15/1998 3:35:00 PM
From: scaram(o)uche  Read Replies (3) of 1826
 
>> Another interesting comment was that the increased Salagen numbers to are not due
to "filling the pipeline" for Sjogren's syndrome, as would be the case with a drug that
was totally new to the market. <<

You mean the entire $500K?

>> They remain confident that a European partner for MGI 114 will become a reality. <<

And here we are upon vacation time again. A year goes by so fast!

From the release.......

"We also observed additional evidence of antitumor activity in
some patients"

A statement that could, someday, invite litigation. Blitzer had better have, in-hand, responses that are classically defined as partial response (or better). Another poorly-defined reference. Did he give additional definition in the conference call?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News